Table 1.
Agents in clinical trials targeting metabolic regulators of the cancer-immunity cycle
| Agenta | Combination Immunotherapy | Clinical Phase | Clinical Trial IdentifierII |
|---|---|---|---|
| A2A receptor inhibitors | |||
| AZD4635 | - | 2 | NCT03381274 |
| AZD4635 | Durvalumabc | 2 |
NCT04089553
NCT04495179 |
| CPI-444 | Atezolizumabc | 2 | NCT03337698 |
| NIR178(PBF-509) | Spartalizumabb | 2 | NCT03207867 |
| NCT02403193 | |||
| A2B receptor inhibitors | |||
| PBF-1129 | - | 1 | NCT03274479 |
| A2A/A2B receptor inhibitors | |||
| Etrumadenant (AB928) | Zimberelimabb | 2 |
NCT04660812
NCT04381832 |
| Etrumadenant (AB928) | Zimberelimabb, Domvanalimabd | 2 |
NCT04262856
NCT04791839 |
| Etrumadenant (AB928) | Atezolizumabc | 2 |
NCT03821246
NCT03555149 NCT03193190 |
| AHR inhibitors | |||
| BAY2416964 | - | 1 | NCT04069026 |
| IK-175 | Nivolumabb | 1 | NCT04200963 |
| ARG inhibitors | |||
| INCB001158 | - | 2 |
NCT03314935
NCT03837509 |
| INCB001158 | Pembrolizumabb | 2 |
NCT03361228
NCT02903914 |
| CD39 antibodies | |||
| IPH5201 | Durvalumabc | 1 | NCT04261075 |
| SRF617 | Pembrolizumabb | 1 | NCT04336098 |
| TTX-030 | Pembrolizumabb, Budigalimabb | 1 | NCT04306900 |
| Pembrolizumabb | NCT03884556 | ||
| CD73 antibodies/inhibitors | |||
| AB680 (inhibitor) | Zimberelimabb | 2 | NCT04660812 |
| BMS-986179 (antibody) | Nivolumabb | 2 | NCT02754141 |
| Oleclumab (antibody) | - | 2 | NCT03381274 |
| Oleclumab (antibody) | Durvalumabc | 2 |
NCT03616886
NCT03875573 NCT03267589 NCT04668300 |
| IDO1 inhibitors | |||
| Epacadostat | Pembrolizumabb | 3 |
NCT03361865
NCT03374488 NCT03358472 NCT03260894 |
| MCT1 inhibitors | |||
| AZD3965 | - | 1 | NCT01791595 |
| NOS inhibitors | |||
| L-NMMA | - | 2 | NCT02834403 |
| L-NMMA | Pembrolizumabb | 2 | NCT04095689 |
a,
Agent(s) in most advanced clinical phase;
b,
anti-PD-1;
c,
anti-PD-L1;
d,
anti-TIGIT.
A2A (ADORA2A), adenosine A2a receptor; A2B (ADORA2B), adenosine A2b receptor; AHR, aryl hydrocarbon receptor; ARG, arginase; CD39 (ENTPD1), cluster of differentiation 39; CD73 (NT5E), cluster of differentiation 73, IDO1, indoleamine 2,3 dioxygenase; MCT1 (SLC16A1), Monocarboxylate Transporter 1; NOS, nitric oxide synthase; TIGIT, T Cell Immunoreceptor with Ig And ITIM Domains.
II
These trials are listed in clinicaltrials.gov with their respective ID numbers.